J Stock Overview
Lotus Ventures Inc. engages in the production, cultivation, and sale of cannabis products for medical purpose in Canada.
Lotus Ventures Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.06|
|52 Week High||CA$0.15|
|52 Week Low||CA$0.05|
|1 Month Change||-7.69%|
|3 Month Change||-14.29%|
|1 Year Change||-58.62%|
|3 Year Change||-65.71%|
|5 Year Change||-82.09%|
|Change since IPO||-64.71%|
Recent News & Updates
Subdued Growth No Barrier To Lotus Ventures Inc. (CSE:J) With Shares Advancing 42%
Lotus Ventures Inc. ( CSE:J ) shares have had a really impressive month, gaining 42% after a shaky period beforehand...
|J||CA Pharmaceuticals||CA Market|
Return vs Industry: J exceeded the Canadian Pharmaceuticals industry which returned -65% over the past year.
Return vs Market: J underperformed the Canadian Market which returned -0.2% over the past year.
|J Average Weekly Movement||14.9%|
|Pharmaceuticals Industry Average Movement||12.6%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||19.0%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: J is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: J's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Lotus Ventures Inc. engages in the production, cultivation, and sale of cannabis products for medical purpose in Canada. The company sells its products under the Lotus Cannabis Co. brand name. Lotus Ventures Inc. was incorporated in 2007 and is based in Vancouver, Canada.
Lotus Ventures Fundamentals Summary
|J fundamental statistics|
Is J overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|J income statement (TTM)|
|Cost of Revenue||CA$984.90k|
Last Reported Earnings
May 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.002|
|Net Profit Margin||7.29%|
How did J perform over the long term?See historical performance and comparison
Is J undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for J?
Other financial metrics that can be useful for relative valuation.
|What is J's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does J's PE Ratio compare to its peers?
|J PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
GRIN Grown Rogue International
AYUR Ayurcann Holdings
EAST EastWest Bioscience
CXXI C21 Investments
J Lotus Ventures
Price-To-Earnings vs Peers: J is expensive based on its Price-To-Earnings Ratio (30x) compared to the peer average (20.8x).
Price to Earnings Ratio vs Industry
How does J's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?
Price-To-Earnings vs Industry: J is expensive based on its Price-To-Earnings Ratio (30x) compared to the Canadian Pharmaceuticals industry average (16.1x)
Price to Earnings Ratio vs Fair Ratio
What is J's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||30x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate J's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of J when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate J's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate J's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Lotus Ventures forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lotus Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Lotus Ventures performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: J has a large one-off gain of CA$157.9K impacting its May 31 2022 financial results.
Growing Profit Margin: J became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: J has become profitable over the past 5 years, growing earnings by 45.1% per year.
Accelerating Growth: J has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: J has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (72.5%).
Return on Equity
High ROE: J's Return on Equity (1.1%) is considered low.
Discover strong past performing companies
How is Lotus Ventures's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: J's short term assets (CA$4.7M) exceed its short term liabilities (CA$1.7M).
Long Term Liabilities: J has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: J's net debt to equity ratio (5.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if J's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: J's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: J's interest payments on its debt are not well covered by EBIT (2.4x coverage).
Discover healthy companies
What is Lotus Ventures's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate J's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate J's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if J's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if J's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as J has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dale McClanaghan (66 yo)
Mr. Dale Bernard McClanaghan, MBA has been the Chief Executive Officer and President of Lotus Ventures Inc. since November 27, 2014. Mr. McClanaghan has been the Chief Executive Officer of BCM Resources Co...
CEO Compensation Analysis
Compensation vs Market: Dale's total compensation ($USD160.24K) is about average for companies of similar size in the Canadian market ($USD188.05K).
Compensation vs Earnings: Dale's compensation has been consistent with company performance over the past year.
Experienced Management: J's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: J's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: J insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lotus Ventures Inc.'s employee growth, exchange listings and data sources
- Name: Lotus Ventures Inc.
- Ticker: J
- Exchange: CNSX
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$5.398m
- Shares outstanding: 89.97m
- Website: https://www.lotuscannabis.ca
- Lotus Ventures Inc.
- 1030 West Georgia Street
- Suite 1010
- British Columbia
- V6E 2Y3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.